Nanoparticle therapy trial
Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nanoparticle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nanomedicine company announced that its lead compound NBTXR3 had received the go-ahead from the French Medicine Agency (AFSSAPS) to enter its first clinical Phase I trial. Up to 60% of cancer patients undergo radiotherapy, a treatment in which radiation is absorbed by water molecules in the tumour’s cells. This creates free radicals that cause damage and lead to local cell death. The interaction is inefficient however, as the majority of radiation energy is not converted into free radicals. Nanobiotix’s solution is to inject a nanoparticle with a diameter of around 50 nanometers and a heavy oxide core that increases radiation absorption by a factor of 10,000. The nanoparticles cause the release of many more free radicals than water, which amplifies the effect of radiation on the tumour cell. Nanobiotix’s lead program NBTXR3 is a formulation for intratumoural injection. A special coating, which is key to the process, allows the nanoparticles to enter the target cells. The company believes that potentially any tumour type would respond to treatment with their nanoparticles in combination with X-ray radiation.